Israel’s Ministry of Health has approved Brainsway to market and sell the deep transcranial magnetic stimulation (TMS) device to four medical centres to treat neurological and psychopathological disorders.

Brainsway TMS systems is a noninvasive device which treats major depression, bipolar disorder and negative symptoms and cognitive impairment in schizophrenic patients.

Brainsway CEO Uzi Sofer said: "We are now working to update indications with the Israeli Ministry of Health to bring them more in line with the approvals that we’ve already received in Europe."